Portfolio manager comments — Q4 2025
The fund delivered positive performance during the period, rising by just over 4% in SEK, but underperforming its benchmark index*.
The companies contributing most positively to fund performance were AstraZeneca, Volvo, and Sandvik. AstraZeneca reported a strong quarterly result and announced an agreement with the US regarding future drug pricing, which is expected to have a less negative impact than previously feared. The early‑cyclical companies Volvo and Sandvik performed well, with Sandvik benefiting in part from positive order intake within its mining‑related operations.
The largest negative impact came from Novo Nordisk, Sweco, and Afry. Novo Nordisk continued to be affected by concerns related to increased competition and regulated drug pricing. The company’s new leadership has increased commercial activity within direct‑to‑consumer channels, and the company has also entered into an agreement in the US regarding future drug pricing within insurance systems, which is considered positive for volume development over the longer term. Sweco and Afry underperformed in the absence of company‑specific news.
During the period, the holding in Epiroc was increased following a decline in valuation, while exposure to Sandvik was reduced after strong share price performance. Holdings in Hexagon and Essity were reduced, while exposure was increased to Atlas Copco and Electrolux Professional, where prospects are considered more attractive. The holding in Sampo was fully divested, as the valuation was considered less attractive after a sharp price increase.
We continue to focus on ensuring that the fund’s companies have sustainable business models and competitive offerings with durable, profitable growth.
* SIX Sweden SRI Index GI